Current challenges in the development of new treatments for lupus
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 78 (6) , 729-735
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a considerable impact on patients’ quality of life. Despite the plethora of clinical trials for SLE since the turn of the millennium, only one new treatment has been approved for the condition, and the overall pace of successful drug development remains slow. Nevertheless, the myriad of clinical studies has yielded insights that have informed and refined our understanding of eligibility criteria, outcome measures and trial design in SLE. In this review, we highlight the achievements of clinical trials as well as the major pitfalls that have been identified in drug development for SLE and, in doing so, identify areas where collaboration and consensus will be important to facilitate progress.Keywords
Funding Information
- UCB Pharma
This publication has 60 references indexed in Scilit:
- Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III StudyArthritis & Rheumatism, 2013
- Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnnals of the Rheumatic Diseases, 2012
- American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisArthritis Care & Research, 2012
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS studyRheumatology, 2009
- A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Care & Research, 2009
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2‐year prospective studyScandinavian Journal of Rheumatology, 2009
- Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosusArthritis & Rheumatism, 2004